Soligenix, in collaboration with the University of Hawaii at Mānoa is developing thermostable alum adjuvanted coronavirus vaccines for protection against coronavirus infections including COVID-2019 infections. Soligenix will utilise ThermoVax® technology which was in-licensed from the University of Colorado, to stabilise components of the vaccines at high temparature. The vaccines will be based on well-defined surface glycoprotein(s) from one or more coronaviruses, including SARS-CoV-2 virus. Initially, the company will focus the development on a SARS-CoV-2 virus vaccine, for the treatment of COVID-2019 infections. Early research is underway in the US.
The vaccines will be made from purified surface glycoprotein(s) from one or more coronaviruses, which will be manufactured with a proprietary insect cell expression system and aluminum salt, (known colloquially as Alum) as an adjuvant to activate cell as well as humoral immunity in heat stable formulation. The Alum adjuvanted vaccines, manufactured using ThermoVax® technology eliminate the need for cold chain production and transportation.
In April 2020, Soligenix signed an agreement with BTG for the exclusive worldwide license of CoVaccine HT™, a novel vaccine adjuvant. CoVaccine HT is component of Soligenix's vaccine technology platform currently being assessed for use against coronaviruses including SARS-CoV-2, the cause of COVID-19. 
In March 2020, Soligenix and John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa) expanded the collaboration to develop thermostable coronavirus vaccines; including a vaccine for COVID-2019 infections. Earlier in May 2015, Soligenix entered into a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa) and Hawaii Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine. Under the terms of the agreement, Soligenix will evaluate its proprietary vaccine thermostabilization technology, ThermoVax™, licensed from the University of Colorado, to stabilize components of the vaccine. Ultimately, the objective is to produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage.  
In January 2011, Soligenix, Inc. entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures. Soligenix has been developing this stabilization technology under an option-to-license agreement from CU that was initiated to support the technology development efforts funded by a $US9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID). The license agreement has an expanded scope for thermostable vaccines for biodefense as well as all potential vaccine indications. The novel technology involves the use of several unique process and formulation steps that fix sensitive vaccine ingredients in native configuration. For biodefense indications, the company is using the stabilization technology to advance RiVax(TM), its subunit vaccine against ricin toxin, as well a subunit vaccine for anthrax prevention. The underlying technology has been developed by Drs. Amber Clausi, John Carpenter and Theodore Randolph at CU-Boulder. The terms of the license were not disclosed.